Blurbs

Billionaire Israel “Izzy” Englander Bets on Troubled Pharma Giants Teva and Valeant, Nixes Acadia

Billionaire Israel “Izzy” Englander, who helmed his fortune from humble, Polish immigrant beginnings took a chance on two giants that have played with …

J.P. Morgan Says Acorda Troubling Parkinson’s Trial Lessens Upside Potential

Acorda Therapeutics Inc (NASDAQ:ACOR) shareholders are spooked right now after the drug maker confirmed yesterday that enrollment in two long-term safety trials for …

H.C. Wainwright Likes Aurinia Pharmaceuticals’ Opportunity at Hand in the Lupus Nephritis Market

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has enticing clinical potential that has caught the eyes of more than one bull who have sounded off on …

Synergy Pharmaceuticals: Should You Buy the Dip Ahead of FDA Approval?

Shares of biopharma Synergy Pharmaceuticals (NASDAQ:SGYP) are now almost half the price one month ago following a controversial equity offering. With prices so …

Cantor Continues to Play It Cautious on Teva Following Management Meeting

Teva Pharmaceutical (NYSE:TEVA) has a few loose ends untied, from generics pressures to brand drug launches and pipelines that still need to prove …

Oppenheimer Gets Bearish on Pricey Roku Stock

Roku Inc (NASDAQ:ROKU) had just had quite the earnings party, with investors sending shares skyrocketing November 9th on back of an impressive first …

Cowen Bets on Immunomedics Securing Accelerated Approval Even After Decreased Overall Survival Seen in IMMU-132 Abstract

Immunomedics, Inc. (NASDAQ:IMMU) left investors worried about its cancer asset IMMU-132 after revealing an abstract at yesterday’s annual San Antonio Breast Cancer Symposium¬† …

BMO Wonders If Valeant Can Keep Up Its Growth Momentum in Key Franchises

Valeant Pharmaceuticals (NYSE:VRX) has attracted a great deal of positive Street buzz after last Tuesday’s posted third quarter beat. BMO analyst Gary Nachman …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts